Cannabis and Your Immune System: What We Know About Cannabinoids and Immunity

One of the most persistent questions in cannabis pharmacology is deceptively simple: does cannabis affect your immune system? The answer, backed by decades of immunology research, is unambiguously yes. The more nuanced question — whether that effect is harmful, beneficial, or contextually dependent — is where the science gets genuinely complicated.

The endocannabinoid system is deeply integrated with immune function. CB2 receptors, one of the two primary cannabinoid receptor types, are expressed at high density on virtually every immune cell type. This is not a peripheral observation — it means the immune system is one of the primary targets of cannabinoid signaling, both endogenous and exogenous. Understanding what happens when you introduce THC or CBD into this system is critical for anyone using cannabis regularly, and especially for individuals with immune-mediated conditions.

CB2 Receptors: The Immune System’s Cannabinoid Interface

While CB1 receptors are concentrated in the brain and nervous system, CB2 receptors are predominantly expressed on immune cells. The distribution is not uniform — different immune cell populations express CB2 at different densities:

This distribution means that cannabinoids have the capacity to influence virtually every arm of the immune response — innate and adaptive, cellular and humoral. The practical question is whether typical human cannabis exposure actually produces meaningful immune effects.

What THC Does to Immune Cells

The bulk of immunological research on cannabis has focused on THC, and the findings consistently show immunosuppressive effects in laboratory settings.

T-cell function. THC suppresses T-cell proliferation, cytokine production, and cytotoxic activity in vitro (cell culture) and in animal models. A 2010 review by Rieder et al. in Life Sciences summarized data from dozens of studies showing that THC reduces the production of pro-inflammatory cytokines including IL-2, IL-12, IFN-gamma, and TNF-alpha while increasing the production of anti-inflammatory cytokines like IL-10.

Macrophage function. THC affects macrophage chemotaxis (migration toward infection sites), phagocytosis (engulfment of pathogens), and antigen presentation. A 2003 study in the Journal of Neuroimmunology found that THC reduced macrophage processing of antigens by approximately 35% in vitro at physiologically relevant concentrations.

Natural killer cells. NK cells are a critical component of innate immunity, responsible for detecting and destroying virus-infected cells and tumor cells. Multiple studies have shown that THC reduces NK cell activity. A 2007 study by Massi et al. in the Journal of Pharmacology and Experimental Therapeutics found that chronic THC administration in mice reduced NK cell cytolytic activity by 40–60%.

B-cells and antibody production. THC can suppress B-cell differentiation and antibody production. A 2015 study in Molecular Pharmacology found that THC reduced IgM antibody production in B-cells by interfering with the NF-kB signaling pathway, which is essential for B-cell activation and maturation.

Apoptosis. THC can induce apoptosis (programmed cell death) in certain immune cell populations, particularly activated T-cells. A 2005 study in Molecular Pharmacology by Lombard et al. demonstrated that THC triggered apoptosis in activated T-cells through a CB2-dependent mechanism.

The Dose-Relevance Problem

Here is where the story gets more nuanced, and where much of the public discussion goes wrong.

Many of the dramatic immunosuppressive effects described above were observed in vitro using THC concentrations that may not accurately reflect what immune cells encounter in a person who smokes or ingests cannabis. Laboratory cell culture studies can expose immune cells to constant, high THC concentrations that may exceed what occurs in vivo.

A 2017 review by Katchan, David, and Shoenfeld published in Autoimmunity Reviews noted this limitation explicitly: the majority of in vitro studies use THC concentrations of 1–10 micromolar, while peak plasma THC levels in regular cannabis users typically reach 0.1–0.5 micromolar. This concentration gap does not invalidate the findings, but it means the magnitude of immune effects in living humans may be smaller than cell culture studies suggest.

Human epidemiological data provides a more mixed picture:

HIV/AIDS. If cannabis significantly impaired immune function, you would expect to see worse outcomes in HIV-positive individuals who use cannabis. Multiple large cohort studies have found no such association. A 2003 study by Abrams et al. in the Annals of Internal Medicine randomized HIV-positive patients to smoked cannabis, oral THC (dronabinol), or placebo for 21 days. Cannabis use did not adversely affect CD4+ or CD8+ T-cell counts, viral load, or protease inhibitor levels. A 2018 systematic review in AIDS and Behavior reached the same conclusion across 14 studies: cannabis use was not associated with worsening HIV disease progression.

Respiratory infection. A 2012 study by Tashkin published in the Annals of the American Thoracic Society reviewed the long-term respiratory effects of habitual cannabis smoking and found no increased risk of lung cancer, COPD, or opportunistic respiratory infections in cannabis-only smokers (excluding tobacco co-users).

COVID-19. During the pandemic, concerns were raised about whether cannabis use might increase susceptibility to SARS-CoV-2 infection or severe COVID-19. A 2022 analysis of UK Biobank data published in Cannabis and Cannabinoid Research found no association between cannabis use and increased risk of severe COVID-19 outcomes after adjusting for confounders.

What CBD Does to the Immune System

CBD’s immune effects are distinct from THC’s and may be more therapeutically relevant for certain conditions.

CBD has relatively low affinity for both CB1 and CB2 receptors. Its immune effects appear to be mediated through multiple non-cannabinoid receptor targets, including PPARgamma (peroxisome proliferator-activated receptor gamma), adenosine A2A receptors, GPR55, and TRPV1 channels.

Anti-inflammatory effects. CBD has consistently demonstrated anti-inflammatory activity across dozens of models. A 2015 review in Bioorganic & Medicinal Chemistry by Burstein summarized CBD’s anti-inflammatory mechanisms, including suppression of TNF-alpha, IL-1beta, IL-6, and other pro-inflammatory cytokines, as well as inhibition of NF-kB nuclear translocation.

T-regulatory cell promotion. Some evidence suggests CBD may promote the function of T-regulatory cells (Tregs), which suppress excessive immune responses and maintain immune tolerance. A 2020 study in Journal of Cellular and Molecular Medicine found that CBD enhanced Treg function in a mouse model of autoimmune hepatitis, reducing liver inflammation.

Reduced immune cell migration. CBD inhibits the migration of immune cells to sites of inflammation. A 2014 study in PLoS ONE showed that CBD reduced neutrophil migration in a model of acute lung inflammation by 60%, through a mechanism involving adenosine A2A receptor activation.

Immunosuppression: When Is It Actually Beneficial?

The immunosuppressive properties of cannabinoids are often framed negatively, as if any reduction in immune function is inherently harmful. This framing misses a critical point: for the estimated 24 million Americans with autoimmune diseases, excessive immune activity is the problem, not a deficiency.

Autoimmune conditions involve the immune system attacking the body’s own tissues. Current treatments — corticosteroids, methotrexate, biologics — all work by suppressing immune function. If cannabinoids can modulate immune activity with an acceptable side effect profile, their immunosuppressive properties become therapeutic rather than harmful.

Research has explored cannabinoid therapy in several autoimmune conditions:

The most advanced clinical application is in multiple sclerosis, where Sativex (nabiximols) — a 1:1 THC:CBD oromucosal spray — is approved in over 25 countries for MS-associated spasticity. Beyond spasticity, some evidence suggests Sativex may have broader immunomodulatory effects that could affect MS disease progression, though this has not been confirmed in trials specifically designed to test that hypothesis.

The Biphasic Pattern Again

As with many cannabis effects, immune modulation appears to follow a biphasic or context-dependent pattern:

Low-dose vs. high-dose. Some studies suggest that low-dose cannabinoid exposure may stimulate certain immune functions while high doses suppress them. A 2009 study in Neuroimmunomodulation by Jean-Gilles et al. found that low concentrations of CBD enhanced TNF-alpha production in macrophages while high concentrations suppressed it.

Acute vs. chronic. Acute THC exposure tends to produce more pronounced immunosuppression than chronic exposure, suggesting that tolerance develops to the immune effects as it does to the psychoactive effects. A 2014 study in AIDS Research and Human Retroviruses found that long-term cannabis users showed less immune suppression per unit of THC exposure than newer users.

Health status. The immune effects of cannabis may differ between healthy individuals and those with immune-mediated diseases. In healthy individuals, modest immunosuppression may have minimal clinical significance. In individuals with autoimmune diseases, the same immunosuppression could be therapeutic. In immunocompromised individuals (transplant recipients, advanced HIV, chemotherapy patients), even modest additional immunosuppression could theoretically be problematic, though the epidemiological data does not show this consistently.

Practical Implications

For the average healthy cannabis user, the immunological effects of cannabis do not appear to translate into clinically meaningful immune impairment. The epidemiological evidence does not show increased infection rates, worse outcomes from infectious diseases, or reduced vaccine efficacy in cannabis users as a population.

For individuals with autoimmune or inflammatory conditions, the immunomodulatory properties of cannabinoids — particularly CBD — are potentially therapeutic and warrant continued research.

For immunocompromised individuals, the data is insufficient to make strong recommendations in either direction. The theoretical concern exists, but the human evidence does not demonstrate clear harm. Still, immunocompromised patients should discuss cannabis use with their physicians and monitor for any changes in their clinical status.

Key takeaways from the immunology literature:

• The endocannabinoid system is a fundamental regulator of immune function, primarily through CB2 receptors on immune cells
• THC is immunosuppressive in laboratory settings, reducing T-cell, NK cell, macrophage, and B-cell function
• The in vivo significance of these effects at typical human cannabis exposure levels is uncertain
• Large human studies do not show increased susceptibility to infection in cannabis users
• CBD has distinct anti-inflammatory properties mediated through non-CB2 mechanisms
• The immunosuppressive properties of cannabinoids may be therapeutically beneficial for autoimmune conditions
• Context matters: the effect of cannabinoids on immunity likely varies with dose, duration, health status, and specific immune challenge

The immune system and the endocannabinoid system have been co-evolving for 500 million years. Their interaction is deeply embedded in mammalian physiology. Understanding that interaction — rather than reducing it to “cannabis is good for immunity” or “cannabis is bad for immunity” — is what the evidence demands.